Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
By
Staff
58 seconds ago
NEW YORK–(BUSINESS WIRE)–#EYEN Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulato
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR
- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia
- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility
- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023
- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021
LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress.
If you’ve been diagnosed with diabetes, you know how complicated it can be to manage this systemic condition that can affect every organ and tissue in your body over time.
But if there’s one thing you may not be thinking about doing but should it’s getting an eye exam as in, ASAP. “The majority of people with diabetes will eventually develop diabetic retinopathy, which is damage to the tiny blood vessels in the eye’s retina,” says Lloyd P. Aiello, M.D., director of the Beetham Eye Institute at the Joslin Diabetes Center in Boston and professor of ophthalmology at Harvard Medical School. “About one-third of those people will go on to develop diabetic macular edema, or DME, which occurs when fluid from those damaged blood vessels leaks into the macula in the center of the retina.” Your chances of developing diabetic retinopathy or DME is not a matter of luck, but directly related to long term blood sugar control.
Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.